After leaving the White House, Vice President Joe Biden plans to consolidate his work on the Cancer Moonshot into an independent, nonprofit organization, while juggling non-cancer programs at two universities.
ST. JUDE CHILDREN'S RESEARCH HOSPITAL opened its Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
The moonshot, The Cancer Letter's biggest area of coverage of 2016, continues into 2017.
In a 17-institution inspection sparked by reports of patient harm and death resulting from power morcellators and contaminated duodenoscopes, FDA found that nearly all hospitals surveyed either failed to report adverse events or didn't have proper reporting and documentation procedures in place.
Rep. Mike Fitzpatrick (R-Pa.), a staunch advocate for mandating individual reporting of adverse events by physicians
JEFFREY DREBIN was named chair of surgery at Memorial Sloan Kettering Cancer Center, a position he will assume early next year. He is the chair of the Department of Surgery at Penn Medicine and the 14th John Rhea Barton Professor of Surgery at the Perelman School of Medicine.
Doug Lowy will continue to lead NCI in his role as acting director in 2017 unless president-elect Donald Trump decides to appoint a different, new director.
AVASTIN (bevacizumab) received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
The Senate approved the 21st Century Cures Act, a wide-ranging bill that authorizes $1.8 billion over seven years for cancer research as well as $500 million over the next decade for FDA to streamline drug and device approval processes.
Operating losses at MD Anderson Cancer Center ballooned again in October—swelling to $60.9 million on top of September's $41.5 million.
